Cathepsin-D in primary breast cancer: Prognostic evaluation involving 2810 patients

British Journal of Cancer

Volumn 79, Issue 2, 1999, Pages 300-307

  Foekens, J A ^a   Look, M P ^b   Bolt De Vries, J ^b   Meijer Van Gelder, M E ^b   Van Putten, W L J ^b   Klijn, J G M ^b  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b NONE

Author keywords

Breast cancer; Breast cancer prognosis; Cathepsin D; Multivariate analysis

Indexed keywords

CATHEPSIN D; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0032919675     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690048     Document Type: Article

References (43)

1. Barlow RE, Bartholomew DJ, Bremner JM and Brunk HD (1972) Statistical Interference Under Order Restrictions. John Wiley & Sons: London
2. Benraad ThJ, Geurts-Moespot A, Sala M, Piffanelli A, Ross A and Foekens JA on behalf of the EORTC Receptor Study Group (1992) Quality control of cathepsin D measurement by the EORTC Receptor Study Group. Eur J Cancer 28: 72-75
3. r 52 000 cathepsin D secreted by breast cancer cells. Cancer Res 48: 3688-3692
4. Briozzo P, Badet J, Capony F, Pieri I, Montcourrier P, Barritault D and Rochefort H (1991) MCF-7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: a permissive role of cathepsin D. Exp Cell Res 194: 252-259
5. Cardiff RD (1994) Cathepsin D and breast cancer: useful? Hum Pathol 25: 847-848
6. Conover CA and De Leon DD (1994) Acid-activated insulin-like growth factor-binding protein-3 proteolysis in normal and transformed cells: role of cathepsin D. J Biol Chem 269: 7076-7080
7. Cox DR (1972) Regression models and life tables. J R Stat Soc 34: 187-220
8. Duffy MJ, O'Grady P, Devaney D, O'Sorian L, Fennelly JJ and Lijnen HJ (1988) Urokinase-plasminogen activator, a marker for aggressive breast cancers. Cancer 62: 531-533
9. Domagala W, Striker G, Szadowska A, Dukowicz A, Weber K and Osborn M (1992) Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry: no correlations with survival at 5 years. Am J Pathol 141: 1003-1012
10. Emmert-Buck MR (1996) Cathepsin D and prognosis in breast cancer: one piece of a larger puzzle? Hum Pathol 27: 869-871
11. EORTC Breast Cancer Cooperative Group (1980) Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 16: 1513-1515
12. Ferrandina G, Scambia G, Bardelli F, Panici PB and Massori A (1997) Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br J Cancer 76: 661-666
13. Foekens JA, Portengen H, van Putten WLJ, Peters HA, Krijnen HLJM, Alexieva-Figusch J and Klijn JGM (1989) Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res 49: 5823-5828
14. Foekens JA, van Putten WLJ, Portengen H, de Koning HYWCM, Thirion B, Alexieva-Figusch J aud Klijn JGM (1993) Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. J Clin Oncol 11: 899-908
15. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Portengen H, Kramer MD, Jänicke F and Klijn JGM (1994) Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648-1658
16. Foekens JA, Berns EMJJ, Look MP and Klijn JGM (1996) Prognostic factors in node-negative breast cancer (1996). In Hormone-Dependent Cancer. Pasqualini JR and Katzenellebogen BS (eds), pp. 217-252. Marcel Dekker: NY
17. Garcia M, Derocq D, Pujol P and Rochefort H (1990) Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene 5: 1809-1814
18. Gray RJ (1992) Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Am Stat Assoc 87: 942-952
19. Henry JA, McCarthy AL, Angus B, Westley BR, May FEB, Nicholson S, Cairns J, Harris AL and Horne CHW (1990) Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. Cancer 65: 265-271
20. Isola J, Weitz S, Visakorpi T, Holli K, Shea R, Khabbaz N and Kallioniemi OP (1993) Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol 11: 36-43
21. Jänicke F, Schmitt M, Hafter R, Hollreider A, Babic R, Ulm K, Grössner W and Graeff H (1990) Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78
22. Joensuu H, Toikkanen S and Isola J (1995) Stromal cell cathepsin D expression and long-term survival in breast cancer. Br J Cancer 71: 155-159
23. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
24. Kute TE, Shao ZM, Sugg NK, Long RT, Russell GB and Case LD (1992) Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 52: 5198-5203
25. Liaudet E, Derocq D, Rochefort H and Garcia M (1995) Transfected cathepsin D stimulates high density cancer cell growth by inactivating secreted growth inhibitors. Cell Growth Differ 6: 1045-1052
26. Nadji M, Fresno M, Nassiri M, Conner G, Herrero A and Morales AR (1996) Cathepsin D in host stromal cells, but not in tumor cells, is associated with aggressive behavior in node-negative breast cancer. Hum Pathol 27: 890-895
27. O'Donoghue AEMA, Poller DN, Bell JA, Galea MH, Elston CW, Blamey RW and Ellis IO (1995) Cathepsin D in primary breast carcinoma: adverse prognosis is associated with expression in cathepsin D in stromal cells. Breast Cancer Res Treatment 33: 137-145
28. Ravdin P (1993) Evaluation of cathepsin D as a prognostic factor in breast cancer. Breast Cancer Res Treatment 24: 219-226
29. Ravdin PM, Tandon AK, Allred CDC, Clark GM, Fuqua SAW, Hilsenbeck SH, Chamness GC and Osborne CK (1994) Cathepsin D by Western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol 12: 467-474
30. Razumovic JJ, Stojkovic RR, Petrovecki M and Gamulin S (1997) Correlation of two methods for determination of cathepsin D in breast carcinoma (immunohistochemistry and ELISA in cytosol). Breast Cancer Res Treatment 43: 117-122
31. Remmele W and Sauer-Manthey J (1993) Comparative biochemical and immunohistochemical studies on the cathepsin D content of human breast cancer. Virchows Arch A Pathol Anat 422: 467-473
32. Rochefort H (1994) Oestrogens, proteases and breast cancer. From cell lines to clinical applications. Eur J Cancer 10: 1583-1586
33. Rochefort H (1996) The prognostic value of cathepsin D in breast cancer. A long road to the clinic. Eur J Cancer 32A: 7-8
34. Roger P, Montcourrier P, Maudelonde T, Brouillet J-P, Pages A, Laffarque F and Rochefort H (1994) Cathepsin D immunostaining in paraffin-embedded breast cancer cells and macrophages: correlation with cytosolic assay. Hum Pathol 25: 863-871
35. Saftig P, Hetman M, Schmahi L, Weber K, Heine L, Mossman H, Koster A, Hess B, Evers M, von Figura K and Peters C (1995) Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J 14: 3599-3608
36. Spyratos F, Brouillet JP, Defrenne A, Hacène K, Rouesse J, Moudelonde T, Brunet M, Andrieu C, Desplaces A and Rochefort H (1989) Cathepsin-D: an independent prognostic factor for metastasis of breast cancer. Lancet i: 1115-1118
37. Tandon AK, Clark GM, Chamness GC, Chirgwin JM and McGuire WL (1990) Cathepsin D and prognosis in breast cancer. N Engl J Med 332: 297-302
38. Têtu B, Brisson J, Côté C, Brisson S, Potvin D and Roberge N (1993) Prognostic significance of cathepsin D expression in node-positive breast carcinoma: an immunohistochemical study. Int J Cancer 55: 429-435
39. r 52 000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49: 6008-6014
40. Vignon F, Capony F, Chambon M, Freiss G, Garcia M and Rochefort H (1986) Autocrine growth stimulation of the MCF-7 breast cancer cells by the estrogen-regulated 52 k protein. Endocrinology 118: 1537-1540
41. Westley BR and Rochefort H (1979) Estradiol induced proteins in the MCF-7 human breast cancer cell line. Biochem Biophys Res Commun 90: 410-416
42. Westley BR and Rochefort H (1980) A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 20: 353-362
43. Westley BR and May FEB (1996) Cathepsin D and breast cancer. Eur J Cancer 32A: 15-24